Cerulea Clinical Trials

Science and Research

EXPLORE/HORIZON

Gene Therapy Study to Evaluate the Safety and Efficacy of GT005 in people with Geographic Atrophy Secondary to Age-Related Macular Degeneration. This study is operated by the Centre for Eye Research Australia.

Overview

This Phase II clinical study is exploring the safety and efficacy of two doses of GT005 administered as a single subretinal injection in people with geographic atrophy secondary to age-related macular degeneration.

Participants are randomised into either a treated or no treatment/control group and will be followed up for 2 years.

  • Principal Investigator
Dr Thomas Edwards

Learn more

View this study at ClinicalTrials.gov

This database listing provides more detailed information about the EXPLORE study.

View this study at ClinicalTrials.gov

This database listing provides more detailed information about the HORIZON study.